Notice Information
Notice Title
Radiopharmaceutical Manufacturing Unit
Notice Description
GSTT is seeking to commission an industry partner to design, build and operate a new, purpose-built Good Manufacturing Practice (GMP)-compliant Radiopharmaceutical Manufacturing Unit to support the growing demand for diagnostic (SPECT and PET) and therapeutic radiopharmaceuticals within close proximity of GSTT. It is anticipated a unit of 1,240 m2 within 1.5 miles of Guy's Hospital will be leased by GSTT and discussions with the landlord are progressing. This initiative aims to establish a hub-and-spoke model, where the new unit will serve as the central hub, and the existing facility at Guy's Hospital will continue as a spoke. This strategic development will: * Increase manufacturing capacity for routine diagnostics and advanced clinical trials for GSTT and for the wider London market. * Ensure equity of patient access to the latest RP diagnostics and therapeutics. * Support innovative clinical research. * Help future-proof Radiopharmacy services by adapting to evolving market demands. * Develop the Radiopharmacy workforce through education and training programmes to ensure they are equipped with the skills and expertise needed to meet the evolving demands of the industry. This initiative is part of GSTT's strategic vision to lead in nuclear medicine, enhancing patient access to advanced diagnostics and therapies while driving innovation in radiopharmaceutical production. The new unit will also serve as a centre for education and training, developing the next generation of radiopharmacists and strengthening GSTT's role as a leader in clinical research and healthcare excellence. The Estimated Total Contract Value including VAT detailed below is illustrative and VAT will only be charged if applicable.
Planning Information
1 Introduction Guy’s and St Thomas’ NHS Foundation Trust (GSTT/the Trust) is pleased to announce an upcoming virtual market engagement event on Friday 19th September 2025 (11:30 – 12:30), in the form of a panel discussion with key stakeholders from GSTT. GSTT invites industry partners to participate in this engagement exercise to explore an exciting Managed Service Agreement (MSA) opportunity for the design, build and delivery of a Radiopharmacy Manufacturing Unit and Services for the Trust. This event aims to introduce the MSA opportunity, gather industry insights, and foster collaboration to shape the future of Radiopharmacy services at GSTT. 2 Objectives of the Market Engagement Event The panel discussion will: • Introduce the MSA opportunity and outline GSTT’s strategic vision for the new unit. • Test and refine the service model and financial framework to ensure alignment with supplier capabilities and market expectations. • Engage with industry stakeholders to gather insights and feedback on the procurement approach and specifications. • Foster collaboration and explore potential strategic partnerships with industry leaders. 3 Scope of the MSA Opportunity The MSA opportunity will encompass: • Design, build, and operation of a future-proofed state-of-the-art GMP-compliant Radiopharmaceutical Manufacturing Unit. • Aseptic manufacturing of diagnostic (SPECT and PET) and therapeutic radiopharmaceuticals for both routine use and clinical trials. • Production of investigational medicinal products (IMP) to support innovative clinical research. • Integration with existing GSTT pathways, ensuring high standards of patient safety and quality assurance. • Cell labelling services. This partnership will require operational excellence, regulatory compliance, and the ability to adapt to evolving market demands. It is anticipated the MSA contract will be awarded for a period of 12 years with an option to extend by a further 5 years. The contract value (exclusive of VAT) is estimated to be £42m for the first 12 years and £27m for the optional extension (total £69m) 4. Managed Service Agreement (MSA) A Managed Service Agreement (MSA) is a contract between an organisation (GSTT) and an external provider (the Supplier) to deliver and manage specific services or operations over an agreed period. Under an MSA, the supplier is responsible for end-to-end management, including staffing, equipment, maintenance, and compliance, ensuring that the service is delivered efficiently and consistently, in accordance with GSTT requirements. 5. Approach to procurement GSTT is planning to undertake a Competitive Flexible Procedure under the Procurement Act 2023 to select the right partner. To ensure transparency and gather industry insights, GSTT is hosting this virtual market engagement event to outline the project’s scope, expectations, and strategic direction. This will be followed by an opportunity for an individual meeting with GSTT to explore the opportunity in more detail. Please confirm your attendance by Wednesday 17th September 2025.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-058bd9
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/050413-2025
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- UK2 - Preliminary Market Engagement Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
09 - Petroleum products, fuel, electricity and other sources of energy
33 - Medical equipments, pharmaceuticals and personal care products
85 - Health and social work services
-
- CPV Codes
09343000 - Radioactive materials
33124000 - Diagnostics and radiodiagnostic devices and supplies
33140000 - Medical consumables
33151000 - Radiotherapy devices and supplies
33151400 - Radiotherapy supplies
33600000 - Pharmaceutical products
33694000 - Diagnostic agents
85145000 - Services provided by medical laboratories
85149000 - Pharmacy services
Notice Value(s)
- Tender Value
- £69,000,000 £10M-£100M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 21 Aug 20256 months ago
- Submission Deadline
- Not specified
- Future Notice Date
- 1 Oct 2025Expired
- Award Date
- Not specified
- Contract Period
- 31 May 2026 - 31 May 2038 Over 5 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planning
- Lots Status
- Planning
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- GUY'S AND ST THOMAS' NHS FOUNDATION TRUST
- Contact Name
- Alizeh Ahmed
- Contact Email
- alizeh.ahmed@nhs.net
- Contact Phone
- Not specified
Buyer Location
- Locality
- LONDON
- Postcode
- SE1 9RT
- Post Town
- South East London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI44 Lewisham and Southwark
- Delivery Location
- TLI London
-
- Local Authority
- Southwark
- Electoral Ward
- London Bridge & West Bermondsey
- Westminster Constituency
- Bermondsey and Old Southwark
Further Information
Notice Documents
-
https://www.find-tender.service.gov.uk/Notice/050413-2025
21st August 2025 - Preliminary market engagement notice on Find a Tender
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-058bd9-2025-08-21T10:13:11+01:00",
"date": "2025-08-21T10:13:11+01:00",
"ocid": "ocds-h6vhtk-058bd9",
"initiationType": "tender",
"parties": [
{
"id": "GB-PPON-PDZC-6438-DGPX",
"name": "Guy's and St Thomas' NHS Foundation Trust",
"identifier": {
"scheme": "GB-PPON",
"id": "PDZC-6438-DGPX"
},
"address": {
"streetAddress": "Great Maze Pond",
"locality": "London",
"postalCode": "SE1 9RT",
"country": "GB",
"countryName": "United Kingdom",
"region": "UKI44"
},
"contactPoint": {
"name": "Alizeh Ahmed",
"email": "alizeh.ahmed@nhs.net"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.guysandstthomas.nhs.uk",
"classifications": [
{
"scheme": "UK_CA_TYPE",
"id": "publicAuthorityCentralGovernment",
"description": "Public authority - central government"
}
]
}
}
],
"buyer": {
"id": "GB-PPON-PDZC-6438-DGPX",
"name": "Guy's and St Thomas' NHS Foundation Trust"
},
"planning": {
"milestones": [
{
"id": "engagement",
"type": "engagement",
"description": "1 Introduction Guy's and St Thomas' NHS Foundation Trust (GSTT/the Trust) is pleased to announce an upcoming virtual market engagement event on Friday 19th September 2025 (11:30 - 12:30), in the form of a panel discussion with key stakeholders from GSTT. GSTT invites industry partners to participate in this engagement exercise to explore an exciting Managed Service Agreement (MSA) opportunity for the design, build and delivery of a Radiopharmacy Manufacturing Unit and Services for the Trust. This event aims to introduce the MSA opportunity, gather industry insights, and foster collaboration to shape the future of Radiopharmacy services at GSTT. 2 Objectives of the Market Engagement Event The panel discussion will: * Introduce the MSA opportunity and outline GSTT's strategic vision for the new unit. * Test and refine the service model and financial framework to ensure alignment with supplier capabilities and market expectations. * Engage with industry stakeholders to gather insights and feedback on the procurement approach and specifications. * Foster collaboration and explore potential strategic partnerships with industry leaders. 3 Scope of the MSA Opportunity The MSA opportunity will encompass: * Design, build, and operation of a future-proofed state-of-the-art GMP-compliant Radiopharmaceutical Manufacturing Unit. * Aseptic manufacturing of diagnostic (SPECT and PET) and therapeutic radiopharmaceuticals for both routine use and clinical trials. * Production of investigational medicinal products (IMP) to support innovative clinical research. * Integration with existing GSTT pathways, ensuring high standards of patient safety and quality assurance. * Cell labelling services. This partnership will require operational excellence, regulatory compliance, and the ability to adapt to evolving market demands. It is anticipated the MSA contract will be awarded for a period of 12 years with an option to extend by a further 5 years. The contract value (exclusive of VAT) is estimated to be PS42m for the first 12 years and PS27m for the optional extension (total PS69m) 4. Managed Service Agreement (MSA) A Managed Service Agreement (MSA) is a contract between an organisation (GSTT) and an external provider (the Supplier) to deliver and manage specific services or operations over an agreed period. Under an MSA, the supplier is responsible for end-to-end management, including staffing, equipment, maintenance, and compliance, ensuring that the service is delivered efficiently and consistently, in accordance with GSTT requirements. 5. Approach to procurement GSTT is planning to undertake a Competitive Flexible Procedure under the Procurement Act 2023 to select the right partner. To ensure transparency and gather industry insights, GSTT is hosting this virtual market engagement event to outline the project's scope, expectations, and strategic direction. This will be followed by an opportunity for an individual meeting with GSTT to explore the opportunity in more detail. Please confirm your attendance by Wednesday 17th September 2025.",
"dueDate": "2025-10-01T23:59:59+01:00",
"status": "scheduled"
}
],
"documents": [
{
"id": "050413-2025",
"documentType": "marketEngagementNotice",
"noticeType": "UK2",
"description": "Preliminary market engagement notice on Find a Tender",
"url": "https://www.find-tender.service.gov.uk/Notice/050413-2025",
"datePublished": "2025-08-21T10:13:11+01:00",
"format": "text/html"
}
]
},
"tender": {
"id": "ST23-P026",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"title": "Radiopharmaceutical Manufacturing Unit",
"description": "GSTT is seeking to commission an industry partner to design, build and operate a new, purpose-built Good Manufacturing Practice (GMP)-compliant Radiopharmaceutical Manufacturing Unit to support the growing demand for diagnostic (SPECT and PET) and therapeutic radiopharmaceuticals within close proximity of GSTT. It is anticipated a unit of 1,240 m2 within 1.5 miles of Guy's Hospital will be leased by GSTT and discussions with the landlord are progressing. This initiative aims to establish a hub-and-spoke model, where the new unit will serve as the central hub, and the existing facility at Guy's Hospital will continue as a spoke. This strategic development will: * Increase manufacturing capacity for routine diagnostics and advanced clinical trials for GSTT and for the wider London market. * Ensure equity of patient access to the latest RP diagnostics and therapeutics. * Support innovative clinical research. * Help future-proof Radiopharmacy services by adapting to evolving market demands. * Develop the Radiopharmacy workforce through education and training programmes to ensure they are equipped with the skills and expertise needed to meet the evolving demands of the industry. This initiative is part of GSTT's strategic vision to lead in nuclear medicine, enhancing patient access to advanced diagnostics and therapies while driving innovation in radiopharmaceutical production. The new unit will also serve as a centre for education and training, developing the next generation of radiopharmacists and strengthening GSTT's role as a leader in clinical research and healthcare excellence. The Estimated Total Contract Value including VAT detailed below is illustrative and VAT will only be charged if applicable.",
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85149000",
"description": "Pharmacy services"
},
{
"scheme": "CPV",
"id": "33151400",
"description": "Radiotherapy supplies"
},
{
"scheme": "CPV",
"id": "33151000",
"description": "Radiotherapy devices and supplies"
},
{
"scheme": "CPV",
"id": "33124000",
"description": "Diagnostics and radiodiagnostic devices and supplies"
},
{
"scheme": "CPV",
"id": "33694000",
"description": "Diagnostic agents"
},
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33140000",
"description": "Medical consumables"
},
{
"scheme": "CPV",
"id": "85145000",
"description": "Services provided by medical laboratories"
},
{
"scheme": "CPV",
"id": "09343000",
"description": "Radioactive materials"
}
],
"deliveryAddresses": [
{
"region": "UKI",
"country": "GB",
"countryName": "United Kingdom"
}
],
"relatedLot": "1"
}
],
"value": {
"amountGross": 82800000,
"amount": 69000000,
"currency": "GBP"
},
"mainProcurementCategory": "services",
"aboveThreshold": true,
"lots": [
{
"id": "1",
"contractPeriod": {
"startDate": "2026-06-01T00:00:00+01:00",
"endDate": "2038-05-31T23:59:59+01:00",
"maxExtentDate": "2043-05-31T23:59:59+01:00"
},
"hasRenewal": true,
"status": "planning"
}
],
"communication": {
"futureNoticeDate": "2025-10-01T23:59:59+01:00"
},
"status": "planning"
},
"language": "en"
}